| ||
| EU grants marketing authorization for Sanofi-aventis Jevtana Pharmaceutical Business Review The European Commission has granted marketing authorization for Sanofi-aventis' Jevtana (cabazitaxel) in conjunction with prednisone/prednisolone to treat the patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a ... See all stories on this topic » |
This as-it-happens Google Alert is brought to you by Google.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment